Emerging Treatments for COPD: Evidence to Date on Revefenacin

References

• Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet. 1997;349(9064):1498–1504. doi:10.1016/S0140-6736(96)07492-2.
   PubMed Web of Science ®Google Scholar
• Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176(6):532–555. doi:10.1164/rccm.200703-456SO.
   PubMed Web of Science ®Google Scholar
• Rycroft CE, Heyes A, Lanza L, et al. Epidemiology of chronic obstructive pulmonary disease: a literature review. Int J Chron Obstruct Pulmon Dis. 2012;7:457–494. doi:10.2147/COPD.S32330.
   PubMed Web of Science ®Google Scholar
• Garcia Rodriguez LA, Wallander MA, Tolosa LB, et al. Chronic obstructive pulmonary disease in UK primary care: incidence and risk factors. COPD. 2009;6(5):369–379. doi:10.1080/15412550903156325.
   PubMedGoogle Scholar
• Mannino DM, Homa DM, Akinbami LJ, et al. Chronic obstructive pulmonary disease surveillance-United States, 1971-2000. Respir Care. 2002;47(10):1184–1199.
   PubMedGoogle Scholar
• Cazzola M, Page CP, Calzetta L, et al. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev. 2012;64(3):450–504. doi:10.1124/pr.111.004580.
   PubMed Web of Science ®Google Scholar
• Baur F, Beattie D, Beer D, et al. The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist. J Med Chem. 2010;53(9):3675–3684. doi:10.1021/jm100068m.
   PubMed Web of Science ®Google Scholar
• Bouyssou T, Hoenke C, Rudolf K, et al. Discovery of olodaterol, a novel inhaled beta2-adrenoceptor agonist with a 24 h bronchodilatory efficacy. Bioorg Med Chem Lett. 2010;20(4):1410–1414. doi:10.1016/j.bmcl.2009.12.087.
   PubMed Web of Science ®Google Scholar
• Slack RJ, Barrett VJ, Morrison VS, et al. In vitro pharmacological characterization of vilanterol, a novel long-acting beta2-adrenoceptor agonist with 24-hour duration of action. J Pharmacol Exp Ther. 2013;344(1):218–230. doi:10.1124/jpet.112.198481.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543–1554. doi:10.1056/NEJMoa0805800.
   PubMed Web of Science ®Google Scholar
• Santus P, Radovanovic D, Paggiaro P, et al. Why use long acting bronchodilators in chronic obstructive lung diseases? An extensive review on formoterol and salmeterol. Eur J Intern Med. 2015;26(6):379–384. doi:10.1016/j.ejim.2015.05.001.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Ferguson GT. Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respir Res. 2013;14(1):49. doi:10.1186/1465-9921-14-49.
   PubMedGoogle Scholar
• Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000;320(7245):1297–1303. doi:10.1136/bmj.320.7245.1297.
   PubMed Web of Science ®Google Scholar
• Sibila O, Soto-Gomez N, Restrepo MI. The risk and outcomes of pneumonia in patients on inhaled corticosteroids. Pulm Pharmacol Ther. 2015;32:130–136. doi:10.1016/j.pupt.2015.04.001.
   PubMed Web of Science ®Google Scholar
• Singh D, Agusti A, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019. Eur Respir J. 2019;53(5). doi:10.1183/13993003.00164-2019.
   Google Scholar
• Mirza S, Clay RD, Koslow MA, et al. COPD guidelines: a review of the 2018 GOLD report. Mayo Clin Proc. 2018;93(10):1488–1502. doi:10.1016/j.mayocp.2018.05.026.
   PubMed Web of Science ®Google Scholar
• Bourbeau J, Aaron SD, Barnes NC, et al. Evaluating the risk of pneumonia with inhaled corticosteroids in COPD: Retrospective database studies have their limitations SA. Respir Med. 2017;123:94–97. doi:10.1016/j.rmed.2016.12.015.
   PubMed Web of Science ®Google Scholar
• Laube BL, Janssens HM, de Jongh FH, et al. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J. 2011;37(6):1308–1331. doi:10.1183/09031936.00166410.
   PubMed Web of Science ®Google Scholar
• Pulido-Rios MT, McNamara A, Obedencio GP, et al. In vivo pharmacological characterization of TD-4208, a novel lung-selective inhaled muscarinic antagonist with sustained bronchoprotective effect in experimental animal models. J Pharmacol Exp Ther. 2013;346(2):241–250. doi:10.1124/jpet.113.203554.
   PubMed Web of Science ®Google Scholar
• Hegde SS, Pulido-Rios MT, Luttmann MA, et al. Pharmacological properties of revefenacin (TD-4208), a novel, nebulized long-acting, and lung selective muscarinic antagonist, at human recombinant muscarinic receptors and in rat, guinea pig, and human isolated airway tissues. Pharmacol Res Perspect. 2018;6(3):e00400. doi:10.1002/prp2.400.
   PubMed Web of Science ®Google Scholar
• Quinn D, Barnes CN, Yates W, et al. Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies. Pulm Pharmacol Ther. 2018;48:71–79. doi:10.1016/j.pupt.2017.10.003.
   PubMed Web of Science ®Google Scholar
• Pudi KK, Barnes CN, Moran EJ, et al. A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease. Respir Res. 2017;18(1):182. doi:10.1186/s12931-017-0647-1.
   PubMed Web of Science ®Google Scholar
• Ferguson GT, Pudi K, Pendyala S, et al. Efficacy of revefenacin, a novel once-daily nebulized long-acting muscarinic antagonist: results of two randomized, double-blind, placebo-controlled, parallel-group phase 3 trials in participants with moderate to very severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;195:A5474.
   Web of Science ®Google Scholar
• Ferguson GT, Feldman G, Pudi KK, et al. Improvements in lung function with nebulized revefenacin in the treatment of patients with moderate to very severe COPD: results from two replicate phase III clinical trials. Chronic Obstr Pulm Dis. 2019;6(2):154–165.
   PubMed Web of Science ®Google Scholar
• Biopharma T. Revefenacin (TD-4208) phase 3 efficacy results [media release]. 13 Nov 2016.
   Google Scholar
• Donohue J, Pendyala S, Barnes C, et al. The 24-hour profile of FEV1 after 12-weeks treatment with revefenacin, a once daily long-acting muscarinic receptor antagonists for nebulization: a spirometry substudy [abstract]. Chest 2017;152(4):A770. doi:10.1016/j.chest.2017.08.801.
   Web of Science ®Google Scholar
• Donahue JF, Sethi S, Barnes CN, et al. COPD exacerbations in the phase 3 revefenacin clinical trial program [abstract]. Eur Resp J. 2018;52(Suppl. 62):OA1655.
   Google Scholar
• Donohue J, Pendyala S, Barnes C, et al. Improvements in health status with revefenacin, a once-daily long-acting muscarinic antagonist for nebulization: changes in St George’s respiratory questionnaire and COPD assessment test in replicate 3-month studies [abstract]. Chest 2017;152(4):A819. doi:10.1016/j.chest.2017.08.850.
   Web of Science ®Google Scholar
• Mahler DA, Ohar JA, Barnes CN, et al. Nebulized versus dry powder long-acting muscarinic antagonist bronchodilators in patients with COPD and suboptimal peak inspiratory flow rate. Chronic Obstr Pulm Dis. 2019;6(4). doi:10.15326/jcopdf.6.4.2019.0137.
   Web of Science ®Google Scholar
• Donohue JF, Kerwin E, Sethi S, et al. Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe Chronic Obstructive Pulmonary Disease (COPD). Respir Res. 2019;20(1):241. doi:10.1186/s12931-019-1187-7.
   PubMed Web of Science ®Google Scholar
• Donohue JF, Kerwin E, Sethi S, et al. Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary disease. Respir Med. 2019; 153:38–43. doi:10.1016/j.rmed.2019.05.010.
   PubMed Web of Science ®Google Scholar
• Borin MT, Lo A, Barnes CN, et al. Pharmacokinetics and safety of revefenacin in subjects with impaired renal or hepatic function. COPD. 2019;14:2305–2318. doi:10.2147/COPD.S203709.
   Google Scholar
• Heo YA. Revefenacin: first global approval. Drugs. 2019;79(1):85–91. doi:10.1007/s40265-018-1036-x.
   PubMed Web of Science ®Google Scholar
• Karner C, Chong J, Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;21(7):CD009285. doi:10.1002/14651858.CD009285.pub3.
   Google Scholar
• Calzetta L, Rogliani P, Ora J, et al. LABA/LAMA combination in COPD: a meta-analysis on the duration of treatment. Eur Respir Rev. 2017;26(143):160043. doi:10.1183/16000617.0043-2016.
   PubMed Web of Science ®Google Scholar
• Vestbo J, Papi A, Corradi M, et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet. 2017;389(10082):1919–1929. doi:10.1016/S0140-6736(17)30188-5.
   PubMed Web of Science ®Google Scholar
• Scichilone N, Benfante A, Bocchino M, et al. Which factors affect the choice of the inhaler in chronic obstructive respiratory diseases? Pulm Pharmacol Ther. 2015;31:63–67. doi:10.1016/j.pupt.2015.02.006.
   PubMed Web of Science ®Google Scholar
• Dalby R, Spallek M, Voshaar T. A review of the development of Respimat Soft Mist Inhaler. Int J Pharm. 2004;283(1–2):1–9. doi:10.1016/j.ijpharm.2004.06.018.
   PubMed Web of Science ®Google Scholar
• Tarsin WY, Pearson SB, Assi KH, et al. Emitted dose estimates from Seretide Diskus and Symbicort Turbuhaler following inhalation by severe asthmatics. Int J Pharm. 2006;316(1–2):131–137. doi:10.1016/j.ijpharm.2006.02.040.
   PubMedGoogle Scholar
• Souza ML, Meneghini AC, Ferraz E, et al. Knowledge of and technique for using inhalation devices among asthma patients and COPD patients. J Bras Pneumol. 2009;35(9):824–831.
   PubMed Web of Science ®Google Scholar
• Melani AS, Bonavia M, Cilenti V, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med. 2011;105(6):930–938. doi:10.1016/j.rmed.2011.01.005.
   PubMed Web of Science ®Google Scholar
• van der Palen J, Klein JJ, Kerkhoff AH, et al. Evaluation of the effectiveness of four different inhalers in patients with chronic obstructive pulmonary disease. Thorax. 1995;50(11):1183–1187. doi:10.1136/thx.50.11.1183.
   PubMed Web of Science ®Google Scholar
• Sulaiman I, Cushen B, Greene G, et al. Objective assessment of adherence to inhalers by patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;195(10):1333–1343. doi:10.1164/rccm.201604-0733OC.
   PubMed Web of Science ®Google Scholar
• Kerwin E, Ferguson GT. An overview of glycopyrrolate/eFlow(R) CS in COPD. Expert Rev Respir Med. 2018;12(6):447–459. doi:10.1080/17476348.2018.1476853.
   PubMed Web of Science ®Google Scholar
• Coleman CI, Limone B, Sobieraj DM, et al. Dosing frequency and medication adherence in chronic disease. JMCP. 2012;18(7):527–539. doi:10.18553/jmcp.2012.18.7.527.
   PubMed Web of Science ®Google Scholar
• Li F, Yang J. Revefenacin for the treatment of chronic obstructive pulmonary disease. Expert Rev Clin Pharmacol. 2019;12(4):293–298. doi:10.1080/17512433.2019.1587292.
   PubMed Web of Science ®Google Scholar